Study of the effects of Salvadora persica extract on blood sugar and lipid profile in diabetic patients (type2)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210906052392N1

Enrollment

120

Registered

2021-10-20

Start date

2021-10-08

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes melitus type 2.

Interventions

Intervention 1: Intervention group: Group 1: Consumption of medicine for 8 weeks, syrup containing S. persica extract in a dose of 150 mg twice a day. Intervention 2: Intervention group: Group 2: Con

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Having type 2 diabetes in the last 10 years Age 60-30 years HbA1c between 5.6 to 7.5 Patient consent to participate in the project

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Use of injectable hypoglycemic drugs (injectable insulin) and oral sulfonylureas Renal or liver failure

Design outcomes

Primary

Measure	Time frame
AST, ALT. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;HbA1c. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;BMI. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;Constipation score. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Using the WEXNER questionnaire.;Gastrointestinal symptoms score. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Researcher-made gastrointestinal symptoms questionnaire.;Urinary symptoms score. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Researcher-made questionnaire on urinary symptoms.;Score of skin symptoms. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Researcher-made skin symptoms questionnaire.;Nervous Symptoms Score. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Researcher-made neurological symptoms questionnaire.;Fasting blood sugar. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;Triglyceride, Cholesterol, HDL. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;Homa IR. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.	—

Measure

Time frame

AST, ALT. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;HbA1c. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;BMI. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;Constipation score. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Using the WEXNER questionnaire.;Gastrointestinal symptoms score. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Researcher-made gastrointestinal symptoms questionnaire.;Urinary symptoms score. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Researcher-made questionnaire on urinary symptoms.;Score of skin symptoms. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Researcher-made skin symptoms questionnaire.;Nervous Symptoms Score. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: Researcher-made neurological symptoms questionnaire.;Fasting blood sugar. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;Triglyceride, Cholesterol, HDL. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.;Homa IR. Timepoint: Before the start of the study, the end of 8 weeks of intervention. Method of measurement: medical lab.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Izadikhah

Esfahan University of Medical Sciences

a.izadikhah@resident.mui.ac.ir+98 31 3448 4777

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026